DK1401438T3 - Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer - Google Patents

Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer

Info

Publication number
DK1401438T3
DK1401438T3 DK01952097T DK01952097T DK1401438T3 DK 1401438 T3 DK1401438 T3 DK 1401438T3 DK 01952097 T DK01952097 T DK 01952097T DK 01952097 T DK01952097 T DK 01952097T DK 1401438 T3 DK1401438 T3 DK 1401438T3
Authority
DK
Denmark
Prior art keywords
cyclopamine
treatment
tumors
cell carcinoma
basal cell
Prior art date
Application number
DK01952097T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1401438(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of DK1401438T3 publication Critical patent/DK1401438T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DK01952097T 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer DK1401438T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
DK1401438T3 true DK1401438T3 (da) 2006-02-13

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01952097T DK1401438T3 (da) 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Country Status (14)

Country Link
EP (4) EP1561464A3 (da)
JP (3) JP2004536045A (da)
KR (1) KR20090125833A (da)
CN (2) CN1525859B (da)
AT (2) ATE305300T1 (da)
AU (1) AU2001272892B8 (da)
BR (1) BR0117063A (da)
CA (1) CA2452151C (da)
DE (2) DE60113733T2 (da)
DK (2) DK1401438T3 (da)
ES (3) ES2250434T3 (da)
PT (1) PT1411938E (da)
RU (1) RU2312661C2 (da)
WO (2) WO2002078703A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
AU2006283040B2 (en) * 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
SG175691A1 (en) * 2006-10-31 2011-11-28 Us Gov Health & Human Serv Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2134719B1 (en) * 2007-03-07 2013-07-17 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
CN101687877B (zh) 2007-03-07 2014-07-23 无限发现股份有限公司 杂环环杷明类似物及其使用方法
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ/スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
DE60028411T2 (de) * 1999-10-13 2007-01-04 Johns Hopkins University School Of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
CA2392958A1 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
BR0117063A (pt) * 2001-07-02 2004-07-27 Sinan Tas Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis

Also Published As

Publication number Publication date
CA2452151C (en) 2012-01-03
WO2002078704A1 (en) 2002-10-10
CN1522146A (zh) 2004-08-18
CN1525859B (zh) 2010-05-05
EP1401438A1 (en) 2004-03-31
EP2862570A1 (en) 2015-04-22
KR20090125833A (ko) 2009-12-07
AU2001272892B8 (en) 2006-05-04
EP1561464A2 (en) 2005-08-10
EP1561464A3 (en) 2007-04-25
ES2246011T3 (es) 2006-02-01
EP2216022B1 (en) 2015-01-07
DK1411938T3 (da) 2005-11-07
WO2002078703A1 (en) 2002-10-10
PT1411938E (pt) 2005-11-30
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
DE60204966D1 (de) 2005-08-11
WO2002078703A8 (en) 2003-06-12
ES2250434T3 (es) 2006-04-16
RU2004103074A (ru) 2005-05-10
JP2004536045A (ja) 2004-12-02
ATE305300T1 (de) 2005-10-15
ATE299022T1 (de) 2005-07-15
DE60113733T2 (de) 2006-06-29
CN1230169C (zh) 2005-12-07
CA2452151A1 (en) 2002-10-10
DE60204966T2 (de) 2006-05-18
DE60113733D1 (de) 2006-02-09
RU2312661C2 (ru) 2007-12-20
JP2014028834A (ja) 2014-02-13
ES2534400T3 (es) 2015-04-22
EP2216022A1 (en) 2010-08-11
AU2001272892B2 (en) 2006-03-16
BR0117063A (pt) 2004-07-27
CN1525859A (zh) 2004-09-01
JP5424923B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
MA26973A1 (fr) Activateurs glucokinase isoindolin-1-one
NZ544472A (en) Compounds and therapeutical use thereof
EP1535610A4 (en) THERAPEUTIC CANCER
ATE408601T1 (de) Fredericamycin-derivate
IL142674A0 (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
PT1242060E (pt) Tratamento da doenca metastatica
NO20032027L (no) Effektive antitumorbehandlinger
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
GB0121490D0 (en) Ciompounds
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
AR028476A1 (es) Tratamiento del cancer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
EP1359909A4 (en) CANCER THERAPY USING TRIPTOLID PRODRUGS
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
DK1124566T3 (da) Ikke-fermenteret osmotisk laxativ til behandling og forebyggelse af colorectale cancere
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
GB0121494D0 (en) Compounds
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin